2型糖尿病 z-bo 2020-11-06 341

　　Objective: To explore the effectiveness and feasibility of vaccine immune intervention with human-derived RBP-4 as the target for insulin resistance, and to provide basic research data for the advancement of new treatment methods for type 2 diabetes.

　　Methods: T7 phage was used as a vector to express human RBP-4 vaccine to subcutaneously immunize type 2 diabetic mice, and an empty vector group and a blank control group were set up. After two immunizations, the humoral immunity level and fasting blood glucose were measured at different time points. Value and body weight, and the animals were sacrificed at 20 weeks for pathological examination.

　　Results: The RBP-4 vaccine effectively induced the production of anti-RBP-4 IgG antibodies, and reached a peak at 12 weeks. At the same time, the fasting blood glucose level of the immunized group gradually decreased from the 8th week, and it was less than the empty carrier group at the 12th week. There is a significant difference between the blank group and the control group, and it is always maintained below the incidence value of type 2 diabetes (7 mmol/L). During the experiment, the type 2 diabetic mice showed no obvious abnormalities such as curling, erect hair, nose scratching, convulsions, etc., and no obvious pathological changes were observed in the heart, liver, spleen, lung, and kidney tissues of the mice in the immune group and the empty carrier group, indicating RBP -4 The vaccine is safe.

　　Conclusion: RBP-4 vaccine can significantly reduce blood sugar in type 2 diabetic mice, and may become a new breakthrough point in the treatment of insulin resistance.